Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neuroendocrine Tumors × Tamoxifen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 133 Neoplasm Metastasis 9 Carcinoma, Intraductal, Noninfiltrating 9 Breast Neoplasms, Male 9 Breast Carcinoma In Situ 7 Neoplasms 5 Ovarian Neoplasms 3 Inflammatory Breast Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Ductal, Breast 3 Urinary Bladder Neoplasms 2 Prostatic Neoplasms 2 Multiple Endocrine Neoplasia Type 1 2 Hot Flashes 2 Gliosarcoma 2 Glioma 2 Glioblastoma 2 Fibroadenoma 2 Fallopian Tube Neoplasms 2 Central Nervous System Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Brain Neoplasms 2 Sleep Wake Disorders 1 Sarcoma 1 Risk Reduction Behavior 1 Recurrence 1 Quality of Life 1 Primary Breast Cancer 1 Precancerous Conditions 1 Patient Acceptance of Health Care 1

Interventions

Everolimus 14 Octreotide 7 lutetium Lu 177 dotatate 6 pasireotide 5 lanreotide 5 Temozolomide 5 Positron Emission Tomography Computed Tomography 5 surufatinib 4 gallium Ga 68 dotatate 4 Sunitinib 4 Data Collection 4 3-Iodobenzylguanidine 4 Etoposide 3 Carboplatin 3 Capecitabine 3 90Y-octreotide, DOTA-Tyr(3)- 3 pentetreotide 2 pembrolizumab 2 pazopanib 2 fosbretabulin 2 fluorodopa F 18 2 avelumab 2 arginyllysine 2 Sorafenib 2 Single Photon Emission Computed Tomography Computed Tomography 2 Positron-Emission Tomography 2 Pemetrexed 2 PM 01183 2 Magnetic Resonance Spectroscopy 2 Irinotecan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03870399 2024-05-06

HORMONET

AC Camargo Cancer Center

Phase 2 Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡